14-day Premium Trial Subscription Try For FreeTry Free
$8.21
-0.290 (-3.41%)
At Close: May 07, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $5.34 $19.02 Tuesday, 7th May 2024 OTLK stock ended at $8.21. This is 3.41% less than the trading day before Monday, 6th May 2024. During the day the stock fluctuated 7.10% from a day low at $8.17 to a day high of $8.75.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical Outlook Therapeutics Inc. prices

Date Open High Low Close Volume
Jan 19, 2024 $0.364 $0.364 $0.343 $0.349 791 855
Jan 18, 2024 $0.370 $0.370 $0.355 $0.357 500 018
Jan 17, 2024 $0.372 $0.384 $0.363 $0.373 506 207
Jan 16, 2024 $0.387 $0.390 $0.362 $0.384 942 793
Jan 12, 2024 $0.381 $0.390 $0.365 $0.368 362 868
Jan 11, 2024 $0.381 $0.387 $0.373 $0.379 449 282
Jan 10, 2024 $0.373 $0.388 $0.372 $0.380 410 201
Jan 09, 2024 $0.384 $0.391 $0.362 $0.372 1 017 410
Jan 08, 2024 $0.399 $0.399 $0.371 $0.380 857 659
Jan 05, 2024 $0.380 $0.398 $0.375 $0.383 617 400
Jan 04, 2024 $0.400 $0.420 $0.380 $0.390 1 253 738
Jan 03, 2024 $0.392 $0.423 $0.390 $0.417 2 757 063
Jan 02, 2024 $0.403 $0.426 $0.392 $0.393 817 447
Dec 29, 2023 $0.449 $0.461 $0.391 $0.394 2 400 943
Dec 28, 2023 $0.469 $0.469 $0.420 $0.427 4 700 787
Dec 27, 2023 $0.500 $0.500 $0.450 $0.463 5 957 545
Dec 26, 2023 $0.430 $0.450 $0.430 $0.446 1 585 318
Dec 22, 2023 $0.440 $0.453 $0.412 $0.423 1 204 877
Dec 21, 2023 $0.436 $0.436 $0.416 $0.428 655 241
Dec 20, 2023 $0.400 $0.464 $0.400 $0.419 1 932 037
Dec 19, 2023 $0.370 $0.415 $0.350 $0.414 2 617 611
Dec 18, 2023 $0.386 $0.408 $0.371 $0.377 1 228 099
Dec 15, 2023 $0.413 $0.440 $0.384 $0.384 1 749 357
Dec 14, 2023 $0.370 $0.420 $0.370 $0.411 898 636
Dec 13, 2023 $0.394 $0.401 $0.370 $0.401 1 078 965
Click to get the best stock tips daily for free!

About Outlook Therapeutics Inc.

Outlook Therapeutics. Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice... OTLK Profile

Golden Star

Ticker Date Change Price
TMO May 02 0.403% $571.25
STNG May 02 0.699% $71.50
DLR May 02 2.58% $140.15
RF May 02 0.97% $19.64
INVH May 02 0.87% $34.50
SMAR May 02 2.24% $38.39
BIRK May 02 0.650% $44.61
FTSL May 02 0.217% $46.11
VCSH May 02 0.287% $76.71
VRNT May 02 2.44% $30.78
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT